Kiromic BioPharma Inc KRBP shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22.
Monday morning, the FDA authorized the company's Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).
The company expects to start the trial in Q2 of 2023.
Deltacel is the company's allogeneic, non-engineered, off-the-shelf Gamma Delta T-cell therapy.
The company submitted the IND application in early April.
Kiromic BioPharma stock is gaining on heavy volume, with a session volume of 3.6 million shares traded, compared to the trailing 100-day volume of 164.038K shares.
According to data from Benzinga Pro, KRBP has a 52-week high of $24.9 and a 52-week low of $2.59.
Price Action: KRBB shares are up 45.70% at $5.20 on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
